James Investment Research Inc. Raises Holdings in Elevance Health, Inc. $ELV

James Investment Research Inc. grew its stake in shares of Elevance Health, Inc. (NYSE:ELV) by 84.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,752 shares of the company’s stock after acquiring an additional 1,264 shares during the quarter. James Investment Research Inc.’s holdings in Elevance Health were worth $806,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of ELV. Kemnay Advisory Services Inc. purchased a new stake in Elevance Health during the 4th quarter worth approximately $31,000. J.Safra Asset Management Corp purchased a new position in shares of Elevance Health in the fourth quarter worth $32,000. ORG Partners LLC lifted its stake in shares of Elevance Health by 120.4% during the fourth quarter. ORG Partners LLC now owns 108 shares of the company’s stock worth $38,000 after buying an additional 59 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA acquired a new stake in shares of Elevance Health during the fourth quarter worth $38,000. Finally, Dorato Capital Management purchased a new stake in shares of Elevance Health during the fourth quarter valued at $41,000. 89.24% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, Director Robert L. Dixon, Jr. sold 151 shares of the business’s stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $401.77, for a total transaction of $60,667.27. Following the completion of the sale, the director directly owned 10,734 shares in the company, valued at approximately $4,312,599.18. The trade was a 1.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.34% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of analysts have commented on ELV shares. UBS Group lifted their price target on Elevance Health from $400.00 to $460.00 and gave the stock a “buy” rating in a research report on Friday, May 22nd. Barclays increased their price objective on Elevance Health from $408.00 to $480.00 and gave the company an “overweight” rating in a report on Tuesday, May 26th. JPMorgan Chase & Co. lifted their target price on Elevance Health from $411.00 to $476.00 and gave the stock an “overweight” rating in a report on Monday, June 8th. Deutsche Bank Aktiengesellschaft upgraded shares of Elevance Health from a “hold” rating to a “buy” rating and increased their price target for the stock from $363.00 to $498.00 in a report on Wednesday, May 20th. Finally, Evercore reissued a “hold” rating on shares of Elevance Health in a research report on Tuesday, May 19th. Fourteen analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $419.16.

Elevance Health Trading Up 0.2%

ELV stock opened at $416.97 on Friday. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.70. Elevance Health, Inc. has a 52-week low of $273.71 and a 52-week high of $427.19. The company’s 50-day simple moving average is $389.48 and its 200-day simple moving average is $350.67. The firm has a market cap of $90.55 billion, a P/E ratio of 17.74, a PEG ratio of 2.36 and a beta of 0.67.

Elevance Health (NYSE:ELV) last issued its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.74 by $1.84. The company had revenue of $49.49 billion for the quarter, compared to the consensus estimate of $48.21 billion. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.Elevance Health’s revenue for the quarter was up 1.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $11.97 earnings per share. Elevance Health has set its FY 2026 guidance at 19.850- EPS. As a group, equities analysts forecast that Elevance Health, Inc. will post 26.86 EPS for the current fiscal year.

Elevance Health Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th were paid a $1.72 dividend. The ex-dividend date of this dividend was Wednesday, June 10th. This represents a $6.88 dividend on an annualized basis and a dividend yield of 1.6%. Elevance Health’s payout ratio is currently 29.26%.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.